- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01298323
Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib Treatment (88)
September 22, 2023 updated by: Genzyme, a Sanofi Company
A Randomized,Int.,Open-Label Phase III Study to Assess the Effect of a Patient Outreach Program on the Percentage of Time Patients With Locally Advanced or Metastatic MTC Experience Grade 2 or Higher AEs in the First 12 Months of Treatment With Vandetanib
The purpose of this study is to evaluate the effect of patient outreach program on the proportion of time patients with MTC experience moderate or severe AEs during first 12 months of treatment with vandetanib
Study Overview
Status
Active, not recruiting
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
205
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
St Leonards, Australia, 2065
- Investigational Site Number 301
-
-
-
-
-
Wien, Austria, 1901
- Investigational Site Number 401
-
-
-
-
-
Bruxelles, Belgium, 1000
- Investigational Site Number 501
-
-
-
-
-
Porto Alegre, Brazil, 90035-003
- Investigational Site Number 701
-
Ribeirão Preto, Brazil, 14048-900
- Investigational Site Number 702
-
-
-
-
-
Sofia, Bulgaria, 1527
- Investigational Site Number 901
-
-
-
-
-
London, Canada, N6A 4L6
- Investigational Site Number 1001
-
Sherbrooke, Canada, J1H 5N4
- Investigational Site Number 1002
-
Toronto, Canada, M5G2M9
- Investigational Site Number 1003
-
-
-
-
-
Beijing, China, 100021
- Investigational Site Number 1301
-
Shanghai, China
- Investigational Site Number 1302
-
-
-
-
-
Praha, Czechia, 15006
- Investigational Site Number 1901
-
-
-
-
-
Odense C, Denmark, 5000
- Investigational Site Number 2001
-
-
-
-
-
Helsinki, Finland, FI-00029
- Investigational Site Number 2201
-
-
-
-
-
Essen, Germany, 45122
- Investigational Site Number 2602
-
Halle, Germany, 06120
- Investigational Site Number 2603
-
Würzburg, Germany, 97080
- Investigational Site Number 2601
-
-
-
-
-
Athens, Greece, 11528
- Investigational Site Number 3001
-
-
-
-
-
Mumbai, India, 400012
- Investigational Site Number 3501
-
Vellore, India, 632004
- Investigational Site Number 3502
-
-
-
-
-
Jerusalem, Israel, 91120
- Investigational Site Number 4001
-
-
-
-
-
Napoli, Italy
- Investigational Site Number 4104
-
Pisa, Italy, 56124
- Investigational Site Number 4101
-
Roma, Italy, 00161
- Investigational Site Number 4102
-
-
-
-
-
Seoul, Korea, Republic of
- Investigational Site Number 6001
-
-
-
-
-
Poznan, Poland, 60-355
- Investigational Site Number 5702
-
Warsaw, Poland, 02-781
- Investigational Site Number 5703
-
-
-
-
-
Moscow, Russian Federation, 115478
- Investigational Site Number 6201
-
Moscow, Russian Federation, 125284
- Investigational Site Number 6204
-
Obninsk, Russian Federation, 249036
- Investigational Site Number 6202
-
St Petersburg, Russian Federation, 197022
- Investigational Site Number 6203
-
-
-
-
-
Uppsala, Sweden, 75185
- Investigational Site Number 7201
-
-
-
-
-
Glasgow, United Kingdom, G120YN
- Investigational Site Number 2802
-
Sutton, United Kingdom, SM25PT
- Investigational Site Number 2801
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Provision of informed consent prior to any study specific procedures
- Female or male aged 18 years and over
- Previously confirmed histological diagnosis of unresectable, locally advanced or metastatic hereditary or sporadic MTC. Documentation must be provided in patient's medical chart
- WHO or ECOG Performance status 0-2
- Negative pregnancy test (urine or serum) for female patients of childbearing potential
Exclusion Criteria:
- Unstable brain metastases or spinal cord compression that require treatment, unless treated at least 4 weeks before first dose and stable without steroid treatment for 10 days
- Major surgery within 4 weeks before randomization
- The last dose of prior chemotherapy received less than 3 weeks prior to randomization
- Radiation therapy not completed prior to the first dose of vandetanib
- Significant cardiac event, superior vena cava syndrome, NYHA classification of heart disease ≥2, within 12 weeks before randomization, or presence of cardiac disease that in the opinion of the Investigator increases risk of ventricular arrhythmia
- Creatinine clearance <30 ml/min (calculated by Cockcroft-Gault formula),Patients with moderate renal impairment, defined as creatinine clearance ≥30 to <50 ml/min, must start vandetanib at a reduced dose of 200 mg
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Vandetanib Control
Control - treatment 300mg vandetanib opel label
|
Treatment 300mg vandetanib opel label.
Other Names:
|
Experimental: Experimental
Experimental - treatment 300mg vandetanib opel label
|
Treatment 300mg vandetanib opel label.
Other Names:
Patients will be contacted at week 1 and then every 2 weeks until completion of 52 weeks to detect/treat AEs sooner
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Time a Patient Experienced at Least 1 AE of CTCAE Grade >=2 in First 12 Months of Receiving Vandetanib in Patients Who Participated in Patient Outreach Program.
Time Frame: 12 months
|
The primary endpoint is the percentage of time a patient experienced at least one AE of CTCAE grade 2 or higher in the first 12 months of treatment with vandetanib.
If the patient discontinues treatment with vandetanib prior to the 12-month time point for any reason, this endpoint will be the time a patient experienced at least one AE of CTCAE grade 2 or higher as a percentage of the time the patient was receiving vandetanib.
|
12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Clinical Sciences & Operations, Sanofi
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 25, 2011
Primary Completion (Actual)
April 26, 2013
Study Completion (Estimated)
June 28, 2024
Study Registration Dates
First Submitted
February 16, 2011
First Submitted That Met QC Criteria
February 16, 2011
First Posted (Estimated)
February 17, 2011
Study Record Updates
Last Update Posted (Actual)
October 2, 2023
Last Update Submitted That Met QC Criteria
September 22, 2023
Last Verified
September 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Adenocarcinoma
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Endocrine System Diseases
- Endocrine Gland Neoplasms
- Head and Neck Neoplasms
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Neuroendocrine Tumors
- Thyroid Diseases
- Thyroid Neoplasms
- Carcinoma, Neuroendocrine
Other Study ID Numbers
- D4200C00088
- 2010-023428-26 (EudraCT Number)
- LPS14815 (Other Identifier: Sanofi)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Medullary Thyroid Cancer
-
University Medical Center GroningenRecruitingMedullary Thyroid Cancer | Thyroid Cancer, Medullary | Medullary Thyroid Carcinoma | Thyroid Carcinoma, MedullaryNetherlands
-
University of WashingtonNational Cancer Institute (NCI)CompletedRecurrent Thyroid Cancer | Thyroid Gland Medullary Carcinoma | Stage IVA Follicular Thyroid Cancer | Stage IVA Papillary Thyroid Cancer | Stage IVB Follicular Thyroid Cancer | Stage IVB Papillary Thyroid Cancer | Stage IVC Follicular Thyroid Cancer | Stage IVC Papillary Thyroid CancerUnited States
-
Genzyme, a Sanofi CompanyCompletedMetastatic Medullary Thyroid CancerBelgium
-
National Cancer Institute (NCI)CompletedInsular Thyroid Cancer | Recurrent Thyroid Cancer | Stage II Follicular Thyroid Cancer | Stage II Papillary Thyroid Cancer | Stage IV Follicular Thyroid Cancer | Stage IV Papillary Thyroid Cancer | Thyroid Gland Medullary CarcinomaUnited States
-
Fondazione Policlinico Universitario Agostino Gemelli...RecruitingThyroid Neoplasms | Thyroid Cancer, Papillary | Thyroid Cancer, Follicular | Thyroid Carcinoma | Thyroid Cancer | Anaplastic Thyroid Cancer | Thyroid Medullary CarcinomaItaly
-
National Cancer Institute (NCI)CompletedRecurrent Thyroid Cancer | Stage IV Follicular Thyroid Cancer | Stage IV Papillary Thyroid Cancer | Thyroid Gland Medullary CarcinomaUnited States
-
University of PennsylvaniaCompletedMetastatic Medullary Thyroid Cancer | Metastatic Differentiated Thyroid Cancer | Metastatic Anaplastic Thyroid Cancer | Metastatic Poorly Differentiated Thyroid CancerUnited States
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingMedullary Thyroid CancerChina
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingAdvanced Thyroid Gland Medullary Carcinoma | Stage III Thyroid Gland Medullary Carcinoma AJCC v8 | Stage IV Thyroid Gland Medullary Carcinoma AJCC v8 | Stage IVA Thyroid Gland Medullary Carcinoma AJCC v8 | Stage IVB Thyroid Gland Medullary Carcinoma AJCC v8 | Stage IVC Thyroid Gland Medullary...United States
-
National Institute of Diabetes and Digestive and...RecruitingNon-Medullary Thyroid CancerUnited States
Clinical Trials on Vandetanib
-
National Cancer Institute (NCI)CompletedRenal Cancer | Von Hippel LindauUnited States
-
Genzyme, a Sanofi CompanyCompleted
-
Genzyme, a Sanofi CompanyCompletedThyroid CancerUnited States, France
-
National Cancer Institute (NCI)CompletedMultiple Endocrine Neoplasia Type 2A | Multiple Endocrine Neoplasia Type 2B | Medullary Thyroid CarcinomaUnited States
-
Samsung Medical CenterAstraZenecaCompleted
-
Genzyme, a Sanofi CompanyCompleted
-
M.D. Anderson Cancer CenterUnited States Department of Defense; AstraZenecaCompleted
-
St. Jude Children's Research HospitalCompletedBrain and Central Nervous System TumorsUnited States
-
Genzyme, a Sanofi CompanyActive, not recruitingTo Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid CancerThyroid CancerUnited States, Italy, Poland, Russian Federation, United Kingdom, Netherlands, Israel, Czechia, India